Knowledge from Corcept’s 178-patient, randomized, managed, Section 2 trial to be featured in a proffered paper oral presentation on the upcoming ESMO convention on September 17, 2021
Outcomes present profit skilled by ladies with recurrent platinum-resistant ovarian most cancers who have been handled with nab-paclitaxel plus Corcept’s proprietary selective cortisol modulator, relacorilant
MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Corcept Therapeutics Integrated (NASDAQ: CORT), a commercial-stage firm engaged within the discovery and growth of medicine to deal with extreme metabolic, oncologic and psychiatric problems by modulating the results of cortisol, right now introduced that outcomes from its 178-patient, randomized, managed, Section 2 trial of relacorilant plus nab-paclitaxel in sufferers with recurrent platinum-resistant ovarian most cancers will probably be featured in a proffered paper oral presentation on the European Society for Medical Oncology (ESMO) Congress 2021. The congress will happen from September 16 – 21, 2021.
“We’re extraordinarily excited by the potential of relacorilant to deal with ladies with recurrent platinum-resistant ovarian most cancers,” stated Joseph Ok. Belanoff, MD, Corcept’s Chief Govt Officer. “As we introduced once we launched our preliminary outcomes, delaying illness development with out rising aspect impact burden was an amazing profit to the ladies on this trial. Within the first quarter of subsequent yr, we plan to provoke a pivotal Section 3 trial to verify these optimistic outcomes.”
Presentation Title: Relacorilant, a selective glucocorticoid receptor modulator, together with nab-paclitaxel improves progression-free survival in sufferers with recurrent platinum-resistant ovarian most cancers: A 3-arm, randomized, open-label, section II research
Speaker: Dr. Domenica Lorusso, Gynecologic Oncology Unit Fondazione Policlinico Universitario Gemelli IRCCS
Presentation Quantity: 721O
Session: Gynecological Cancers Proffered Paper Session
Presentation Date/Time: Friday, September 17, 2021 at 13:40 – 13:50 CEST | Channel 3
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that doesn’t bind to the physique’s different hormone receptors. Corcept is learning relacorilant in quite a lot of critical problems, together with ovarian, adrenal and castration-resistant prostate most cancers and Cushing’s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and technique of use patents. It has obtained orphan drug designation in the USA for the therapy of Cushing’s syndrome and pancreatic most cancers.
About Corcept Therapeutics
Corcept is a commercial-stage firm engaged within the discovery and growth of medicine to deal with extreme metabolic, oncologic and psychiatric problems by modulating the results of the hormone cortisol. Korlym® was the primary drug permitted by the U.S. Meals and Drug Administration for sufferers with Cushing’s syndrome. Corcept has found a big portfolio of proprietary compounds, together with relacorilant, that selectively modulate the results of cortisol. The corporate owns in depth United States and overseas mental property masking the composition of its selective cortisol modulators and using cortisol modulators to deal with quite a lot of critical problems.
Ahead Trying Statements
Statements on this press launch, apart from statements of historic truth, are forward-looking statements based mostly on our present plans and expectations which might be topic to dangers and uncertainties that may trigger our precise outcomes to vary materially from these such statements categorical or indicate. These dangers and uncertainties concern, however aren’t restricted to, the design and outcomes of our medical trials; our skill to realize our objectives throughout the COVID-19 pandemic; the event of relacorilant as a therapy for ovarian most cancers, together with its medical attributes, regulatory approvals, mandates and oversight, and different necessities; and the scope and protecting energy of our mental property. On this press launch, forward-looking statements, embrace these regarding the medical attributes of relacorilant and its potential advantages in sufferers with ovarian most cancers, outcomes of our Section 2 trial and our planning for a Section 3 pivotal trial. These and different dangers are set forth in our SEC filings, which can be found at our web site and the SEC’s web site. We disclaim any intention or obligation to replace forward-looking statements made on this press launch.